Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

NCT ID: NCT07337902

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2029-07-31

Brief Summary

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys.

During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home.

Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned.

Before each menstrual cycle, participants will submit a stool sample and fill out a short (<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Conditions

Crohn's Disease (CD); Dysmenorrhea Primary

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Acetaminophen, Ibuprofen, Acetaminophen, Ibuprofen

Participants will receive medications for each of four menstrual cycles in the following order: 1. Acetaminophen 2. Ibuprofen 3. Acetaminophen 4. Ibuprofen

Group Type: EXPERIMENTAL

Ibuprofen

Intervention Type: OTHER

Participants will receive oral ibuprofen 400 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Acetaminophen

Intervention Type: OTHER

Participants will receive oral acetaminophen 650 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Acetaminophen, Ibuprofen, Ibuprofen, Acetaminophen

Participants will receive medications for each of four menstrual cycles in the following order: 1. Acetaminophen 2. Ibuprofen 3. Ibuprofen 4. Acetaminophen

Group Type: EXPERIMENTAL

Ibuprofen

Intervention Type: OTHER

Participants will receive oral ibuprofen 400 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Acetaminophen

Intervention Type: OTHER

Participants will receive oral acetaminophen 650 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Ibuprofen, Acetaminophen, Ibuprofen, Acetaminophen

Participants will receive medications for each of four menstrual cycles in the following order: 1. Ibuprofen 2. Acetaminophen 3. Ibuprofen 4. Acetaminophen

Group Type: EXPERIMENTAL

Ibuprofen

Intervention Type: OTHER

Participants will receive oral ibuprofen 400 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Acetaminophen

Intervention Type: OTHER

Participants will receive oral acetaminophen 650 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Ibuprofen, Acetaminophen, Acetaminophen, Ibuprofen

Participants will receive medications for each of four menstrual cycles in the following order: 1. Ibuprofen 2. Acetaminophen 3. Acetaminophen 4. Ibuprofen

Group Type: EXPERIMENTAL

Ibuprofen

Intervention Type: OTHER

Participants will receive oral ibuprofen 400 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Acetaminophen

Intervention Type: OTHER

Participants will receive oral acetaminophen 650 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Interventions

Ibuprofen

Participants will receive oral ibuprofen 400 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Intervention Type: OTHER

Acetaminophen

Participants will receive oral acetaminophen 650 mg three times daily for three days during two of four menstrual cycles by random assignment at the onset of cramps.

Intervention Type: OTHER

Other Intervention Names

Tylenol; Advil

Eligibility Criteria

Inclusion Criteria

• Ages 18-44 years
• Assigned female at birth
• Crohn's Disease (CD) diagnosis
• In stable clinical remission from CD, defined as a short Crohn's Disease Activity Index (CDAI; See Table 3) <150 without use of corticosteroids
• Self-reported primary dysmenorrhea
• Regular menstrual cycles occurring every 23-35 days
• Using an appropriate contraceptive method or abstinence

Exclusion Criteria

• Any of the following conditions: endometriosis, adenomyosis, polycystic ovarian syndrome, endometrial fibroids/polyps, chronic pelvic inflammatory disease, a history of pelvic surgery including hysterectomy, any other pathological pelvic conditions, or current pregnancy
• Plans to become pregnant during the study period
• Use of an oral contraceptive for less than 3 months, on an unstable oral contraceptive dose within the last 3 months, switched from one oral contraceptive to another within the last 3 months or intend to do so during the course of the trial
• Taking hormone therapy including estrogen or progesterone that is not part of a hormonal contraceptive
• Known hypersensitivity or contraindication to ibuprofen or acetaminophen
• Inability to complete REDCap questionnaires (including confusion despite training and/or lack of smart phone and/or computer access).
• Not able to speak and read English language.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 44 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

American College of Gastroenterology

OTHER

Sponsor Role: collaborator

University of North Carolina, Chapel Hill

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erica J Brenner, MD, MSCR

Role: PRINCIPAL_INVESTIGATOR

University of North Carolina, Chapel Hill

Locations

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Countries

United States

Facility Contacts

Rachel Cooke, MS

Role: primary

rachel_cooke@med.unc.edu

919-964-2141

Other Identifiers

24-2940

Identifier Type: -

Identifier Source: org_study_id